US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too
Executive Summary
Drug manufacturer reimbursement support services also are garnering a growing amount of enforcement attention, and misleading promotion - whether on- or off-label - remains on the radar of government investigators.
You may also be interested in...
GMP Violations Won’t Trigger Breach Of DOJ Compliance Agreement, Government Attorneys Say
Responding to concerns about ‘over criminalization’ of companies subject to deferred prosecution agreements, FDA and DOJ attorneys note that getting a form 483 won’t breach compliance provisions. Avanos Medical’s 2021 agreement is to be model going forward.
GMP Violations Won’t Trigger Breach Of DOJ Compliance Agreement, Government Attorneys Say
Responding to concerns about ‘over criminalization’ of companies subject to deferred prosecution agreements, FDA and DOJ attorneys note that getting a form 483 won’t breach compliance provisions. Avanos Medical’s 2021 agreement is to be model going forward.
Opioid Labeling Instructions On Naloxone Are Compromise In Co-Prescribing Debate
US FDA says opioid and opioid use disorder treatment labels should suggest providers discuss naloxone availability with patients and caregivers and consider co-prescribing to patients at high-risk of overdose, but it does not mandate co-prescribing, the most aggressive (and costly) option that had been considered.